Aurobindo Pharma revenue surged in Q2 FY27, with profits up 32.5%. Discover the key factors behind this remarkable growth.
FCX Q3 earnings: Best results driven by strong pricing
FCX Q3 earnings show impressive performance with strong copper pricing boosting results.
